Related Experiment Video

Updated: Aug 18, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Anti-epidermal growth factor receptor drugs in cancer therapy

Fortunato Ciardiello1, Giampaolo Tortora

  • 1Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università di Napoli Federico II, Via S. Pansini 5, 80131 Naples, Italy. fortunatociardiello@yahoo.com

Expert Opinion on Investigational Drugs
|May 31, 2002
PubMed

Insights

Targeting the epidermal growth factor receptor (EGFR) with new therapies shows promise for cancer treatment. Monoclonal antibodies and tyrosine kinase inhibitors are demonstrating acceptable tolerability and clinical activity in advanced cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) is a key cell membrane receptor implicated in cancer development and progression.
  • EGFR signaling pathways regulate critical processes including cell proliferation, apoptosis, angiogenesis, and metastasis in epithelial cancers.

Purpose of the Study:

  • To review promising therapeutic strategies targeting the epidermal growth factor receptor for cancer therapy.
  • To highlight the clinical development and early trial results of novel anti-EGFR agents.

Main Methods:

  • Review of ongoing clinical trials for anti-EGFR agents.
  • Analysis of Phase I-II trial data for efficacy and tolerability.

Main Results:

  • Several anti-EGFR agents, including monoclonal antibodies (e.g., cetuximab) and small molecule tyrosine kinase inhibitors (e.g., Tarceva, Iressa), are in Phase II and III development.
  • Early trials indicate acceptable tolerability and notable clinical activity for these agents in various advanced cancer types, both as monotherapy and in combination treatments.

Conclusions:

  • Targeting the epidermal growth factor receptor is a valuable molecular approach in cancer therapy.
  • Emerging anti-EGFR drugs show potential for treating advanced cancers with acceptable safety and efficacy profiles.

More Related Videos

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay05:21

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay

Published on: September 13, 2024

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K